Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.42    
    

[IMMUNICON
LOGO] 

February 21,
2002 

Paul
A. Liberti, Ph.D.

Unit 305

7225 Pelican Bay Blvd.

Naples, FL 34108 

Re: Consulting Agreement ("Agreement") with Immunicon Corporation effective January 1, 2000, through January 1, 2002  

Dear Dr. Liberti: 

Immunicon
Corporation wishes to extend and amend this Agreement as provided below. 

The Agreement will be extended as follows:  

In Paragraph 2, second line, "for a period of two years" shall be replaced by "through September 20, 2002." 

During the extension of the Term referred to above, the following amendments will apply to this Agreement:

In
the introductory paragraph, "Pennsylvania" shall be replaced by "Delaware." 

Paragraph 1
shall be replaced in its entirety by the following: 

        "1.
Engagement as Consultant; Independent Contractor. Immunicon hereby retains Consultant to provide services including consultation,
advice and assistance to Immunicon in the Field, and Consultant hereby accepts such engagement and agrees to provide such services in accordance with the terms and conditions set forth herein. It is
the express intent of the parties that Consultant is an independent contractor, and not an employee, agent, joint venturer or partner of Immunicon. Nothing in this Agreement shall be interpreted or
construed as creating or establishing the relationship of employer and employee between Immunicon and Consultant, and Consultant shall not have any authority to make any representation or warranty or
to assume or create any obligation, whether express or implied, on behalf of Immunicon or to incur any obligations on behalf of Immunicon without the express written consent of Immunicon. Both parties
acknowledge that Consultant is not an employee for state or federal tax purposes. Consultant shall not be eligible to participate in any employee fringe benefit of Immunicon, including health
insurance, dental insurance, paid vacation, or any other benefit plan of Immunicon. Consultant shall at all times exercise independent judgment in the performance of services hereunder, and shall
retain the right to perform services for others during the term of this Agreement. Consultant shall not perform services under this Agreement at Immunicon's place of business unless the parties
otherwise agree. As Consultant is not Immunicon's employee, Consultant is responsible for paying all required state and federal taxes or other amounts due as a result of payments by Immunicon under
this Agreement. In particular, Immunicon shall not: (i) withhold FICA from Consultant's payments; (ii) make state or federal unemployment insurance contributions on behalf of Consultant;
(iii) withhold state or federal income tax from the 

payments
to Consultant; (iv) make disability insurance contributions on behalf of Consultant; or (v) obtain workers' compensation insurance on behalf of Consultant. However, Immunicon
may, at its sole discretion, report its payments to Consultant to appropriate state and federal government agencies." 

It
is understood and agreed that all of the remaining terms and conditions of the Agreement which are not amended as set forth above shall remain unchanged and in full force and effect during this
extension period and any renewal thereof. 

If
you are in agreement with the foregoing, please so indicate by signing both copies of this letter where indicated below, and return one signed copy to me. 

	Sincerely,	 	Accepted and Agreed:
	IMMUNICON CORPORATION	 	Paul A. Liberti, Ph.D.
	

/s/ Edward L. Erickson
	
 	

/s/ Paul A. Liberti

	Edward L. Erickson	 	 
	Chairman, President and CEO	 	Date of Signature: 2/22/02

QuickLinks

Exhibit 10.42QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.43    
    

[IMMUNICON
LOGO] 

September 16,
2002 

Paul
A. Liberti, Ph.D.

Unit 305

7225 Pelican Bay Blvd.

Naples, FL 34108 

Re: Consulting Agreement ("Agreement") with Immunicon Corporation effective January 1, 2000, through January 1, 2002, as amended and extended to
September 20, 2002  

Dear
Dr. Liberti: 

Immunicon
Corporation wishes to further extend and amend this Agreement as provided below. 

The Agreement, as amended and extended to September 20, 2002, will be further extended and amended, effective September 20, 2002, as
follows:

Paragraph 2
is hereby replaced in its entirety with the following: 

The
Term of this Consulting Agreement (the "Term") shall commence as of September 20, 2002 (the "Effective Date") and shall continue through December 31, 2003, unless this Agreement is
sooner terminated in accordance with the provisions of Section 8 hereof, and shall be automatically renewed under the same terms and conditions as set forth herein, for successive
one-year periods thereafter, unless terminated by either Immunicon or Consultant by the giving of written notice of termination to the other party at least thirty (30) days prior to
the end of any such one-year extension. 

The
first sentence of Paragraph 3 is amended to read as follows: 

During
the Term, Consultant agrees to consult with, advise and assist Immunicon in the Field, and in accordance with the specific duties and responsibilities set forth in Attachment A. 

During this further extension of the Term referred to above, the following amendments will apply to Attachment A of this Agreement:

The
paragraph entitled "Field and Duties" is amended to read: 

Consultant
will provide advice and assistance to Immunicon broadly in the field of analytical chemistry and methods and general business matters, serve as a member of the Scientific Advisory Board of
Immunicon, lead the Immunicon grant applications program, consult on Immunicon's intellectual property program and assist Immunicon personnel with respect to patent preparation and prosecution and
other Intellectual property matters as requested, provide advice and consultation as Immunicon's Chief Technical Officer, and assist in identifying niche opportunities for Immunicon's magnetic
particle/separation technologies. In particular, Consultant shall devote substantial effort to identifying and assisting in the acquiring of "non-traditional" funding for Immunicon, such
as, without limitation, governmental and other institutional grants. 

The
paragraph entitled "Compensation" is amended by adding at the end thereof the following: 

Consultant
additionally will be compensated by being paid a cash bonus of five percent (5%) of the total net direct cash flow to Immunicon and actually received by Immunicon, resulting from
Consultant's identification and acquisition of the "non-traditional" funding as set forth above; provided that if such funding or any portion thereof is provided to another institution or
entity but is determined by Immunicon's management to be directly of business benefit to Immunicon, Consultant will be paid two and one-half percent (21/2%) of the total net
amount of such funding actually received by the other institution or entity. The total amount of the cash bonus paid to Consultant in each twelve-month period of the Term of this Agreement, regardless
of the amount of "non-traditional" funding received 

by
Immunicon or the above-mentioned institutions or entities, will not exceed seventy five thousand dollars ($75,000). Consultant will also be reimbursed his ordinary, reasonable and necessary
business expenses, such as airfare, rental car and hotel expenses, connected with his efforts in identifying and acquiring such "non-traditional" funding on behalf of Immunicon, provided
that any portion of such expenses totaling more than $4500 in any twelve-month period of the Term of this Agreement shall be approved in advance by Immunicon prior to being reimbursed. 

It
is understood and agreed that all of the remaining terms and conditions of the Agreement which are not amended as set forth above shall remain unchanged and in full force and effect during this
extension period and any renewal thereof. 

If
you are in agreement with the foregoing, please so indicate by signing both copies of this letter where indicated below, and return one signed copy to me. 

	Sincerely,	 	Accepted and Agreed:
	IMMUNICON CORPORATION	 	Paul A. Liberti, Ph.D.
	

/s/  EDWARD L ERICKSON      
	
 	

/s/  PAUL A. LIBERTI      

	Edward L. Erickson

Chairman, President and CEO	 	Date of Signature: 9/23/02.

QuickLinks

Exhibit 10.43QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.44    
    

November 18,
2003 

Paul
A. Liberti, Ph.D.

Unit 305

7225 Pelican Bay Blvd.

Naples, FL 34108 

Re: Your Consulting Agreement with Immunicon Corporation effective January 1, 2000, as amended and extended through December 31, 2003
("Agreement")

Dear
Paul: 

Immunicon
Corporation wishes to extend and among the above captioned Agreement as provided below. 

Paragraph 2 of the Agreement, as amended by the letter amendment dated September 16, 2002, is hereby replaced in its entirety with the
following:

        2.  Term. The term of this Consulting Agreement (the "Term") shall continue through March 18, 2007, unless this Consulting Agreement
is terminated in accordance with the provisions of Paragraph 8 hereof. 

Paragraph 8 of the Agreement is hereby replaced in its entirety with the following:

        8.
Termination. This Consulting Agreement is valid for the Term. During the Term this Agreement may be terminated at any time by mutual
agreement of the parties in writing, and by either party hereto
upon the giving of written notice of termination to the other party at least twelve (12) months prior to the date of termination. 

During the extension of the Term referred to in Paragraph 2 of the Agreement above, Attachment A of the Agreement is hereby replaced in its entirety by the
following:

Attachment
A 

Field &
Duties: Effective on the 68th birthday of Consultant, March 18, 2004, Consultant shall resign as the Chief Technical Officer of Immunicon. During the Term of this
Consulting Agreement, Consultant will provide advice and assistance to Immunicon broadly in the field of analytical chemistry and methods, particularly Immunicon's magnetic separation technologies,
and general business matters, serve as a member of the Scientific Advisory Board of Immunicon, consult on Immunicon's intellectual property program, assist Immunicon personnel with respect to patent
preparation and prosecution and other intellectual property matters as requested, and provide such other advice and 

assistance
to Immunicon's management and other personnel as may be requested by them from time to time during the Term of this Consulting Agreement. 

Compensation:
Consultant will be compensated at the rate of $300/hr., with a minimum retainer of $5,100 per month, and with a maximum guideline amount in any month of $7,200, not including the items
listed below. In the event Consultant's services requested by Immunicon exceed 17 hours in any month, Immunicon and Consultant will mutually agree on a project specific plan covering the scope
of the project, amount of time and expected completion date, prior to Consultant commencing services in excess of 17 hours per month. In addition, Consultant shall be granted, consistent with
stock option grants to other members of Immunicon's Scientific Advisory Board, a non-statutory stock option of 15,000 shares of Immunicon common stock, vesting over a period of
4 years from the grant date, the date of such grant to be established by the Board of Directors of Immunicon and such grant being subject to a separate written Stock Option Agreement between
Immunicon and Consultant. Further, Immunicon shall pay to Consultant, in a lump sum payment on or before December 31, 2003, any remaining unpaid compensation due Consultant under this
Consulting Agreement accrued prior to such date, upon receipt and approval by Immunicon of an invoice detailing such accrued compensation, except that such amount shall not exceed $60,000, plus travel
and direct business expenses associated therewith accrued by Consultant in accordance with current travel and expense policies of Immunicon. Immunicon shall also reimburse Consultant for his fair and
reasonable, documented, travel and direct business expenses associated with membership on the Scientific Advisory Board and other services under this Agreement, and in accordance with current travel
and expense policies of Immunicon 

It
is understood and agreed that all of the remaining terms and conditions of the Agreement which are not amended as set forth above shall remain unchanged and in full force and effect during this
extension period and any renewal thereof. 

If
you are in agreement with the foregoing, please so indicate by signing both copies of this letter where indicated below, and return one signed copy to me. 

	Sincerely,	 	Accepted and Agreed:
	IMMUNICON CORPORATION	 	Paul A. Liberti, Ph.D.
	

 	
 	

/s/ Paul A. Liberti
	
	 	

	Edward L. Erickson	 	 
	Chairman, President and CEO	 	Date of Signature: 11/21/03

QuickLinks

Exhibit 10.44

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}]]